Results 221 to 230 of about 75,785 (301)

Neurological implications of chimeric antigen receptor-T cell therapy. [PDF]

open access: yesBMJ Neurol Open
Raffoul DG   +15 more
europepmc   +1 more source

Impact of G‐CSF on Donor TCR Clonal Diversity and T Cell Function During Donor HSC Mobilisation

open access: yesCell Proliferation, EarlyView.
In this study, we found that G‐CSF mobilisation caused a reduction in TCR clonal diversity and down‐regulation of T‐cell function in donors. This may be one of the reasons for the low incidence of GVHD mediated by G‐CSF after allo‐HSCT. Source: Created in BioRender. Li https://BioRender.com/otownki.
Xinye Li   +14 more
wiley   +1 more source

Association Between Plasma Antibody Responses and Risk for Cryptococcus-Associated Immune Reconstitution Inflammatory Syndrome

open access: yes, 2019
Carreño, L.   +9 more
core   +1 more source

Ph‐Negative Acute Lymphoblastic Leukemia in the Older Adults: Biology, Therapeutic Strategies and Unmet Needs

open access: yesEuropean Journal of Haematology, EarlyView.
ABSTRACT Acute lymphoblastic leukaemia (ALL) in older adults represents a growing clinical challenge, driven by an ageing population, adverse disease biology, and reduced tolerance to intensive chemotherapy. Although pediatric‐inspired regimens have improved outcomes in younger adults with Philadelphia chromosome (Ph)‐negative ALL, survival in older ...
Antonella Bruzzese   +12 more
wiley   +1 more source

T cell-inspired therapeutic delivery platforms: From nanomedicines to cell therapy. [PDF]

open access: yesMater Today Bio
Jan N   +6 more
europepmc   +1 more source

Loncastuximab Tesirine in Relapsed/Refractory Diffuse Large B‐Cell Lymphoma: Evidence and Practical Guidance From Italian Clinical Experience

open access: yesEuropean Journal of Haematology, EarlyView.
ABSTRACT Patients with relapsed/refractory (R/R) diffuse large B‐cell lymphoma (DLBCL) who progress to the third‐line setting face a lack of standardized treatment, despite the presence of multiple available therapies. In this context, antibody–drug conjugates represent a relatively new class of anticancer agents; among them, loncastuximab tesirine is ...
Francesca Bonello   +7 more
wiley   +1 more source

Circulating CAR T‐Cells After Treatment With Axicabtagene Ciloleucel in Patients With Relapsed/Refractory Aggressive B‐Cell Lymphomas and Its Association to Treatment Outcome

open access: yesEuropean Journal of Haematology, EarlyView.
ABSTRACT Objectives This study investigates the expansion of CAR T‐cells and its association to treatment outcome. Methods Patients with aggressive B‐cell lymphomas treated with anti‐CD19 CAR T‐cell therapy axicabtagene ciloleucel (axi‐cel) at Skåne and Sahlgrenska University Hospitals from 2019 to October 2024 were included.
Louise Olsson Werne   +6 more
wiley   +1 more source

Bone Marrow Pathology in Cold Agglutinin‐Mediated Autoimmune Hemolytic Anemia: A Study of 56 Cases

open access: yesEuropean Journal of Haematology, EarlyView.
ABSTRACT Cold agglutinin disease (CAD) is a rare form of autoimmune hemolytic anemia (AIHA). CAD occurs in the context of a small clonal B‐cell lymphoproliferation restricted to blood and/or bone marrow (BM), without overt or extramedullary lymphoma. The WHO‐HAEM5 introduced a description of the CAD‐associated lymphoproliferative disorder (CAD‐LPD) in ...
Anne‐Marie L. Becking   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy